These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

536 related articles for article (PubMed ID: 17618536)

  • 1. Levodopa-induced dyskinesia in Parkinson's disease: epidemiology, etiology, and treatment.
    Zesiewicz TA; Sullivan KL; Hauser RA
    Curr Neurol Neurosci Rep; 2007 Jul; 7(4):302-10. PubMed ID: 17618536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levodopa-induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment.
    Thanvi B; Lo N; Robinson T
    Postgrad Med J; 2007 Jun; 83(980):384-8. PubMed ID: 17551069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
    Kwon DK; Kwatra M; Wang J; Ko HS
    Cells; 2022 Nov; 11(23):. PubMed ID: 36496996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Dyskinesia in Parkinson's disease: an update on new neuroimaging methods and treatment possibilities].
    Thomsen BL; Herz DM; Siebner HR; Løkkegaard A
    Ugeskr Laeger; 2017 Mar; 179(10):. PubMed ID: 28263159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
    Dashtipour K; Tafreshi AR; Pahwa R; Lyons KE
    Expert Rev Neurother; 2019 Apr; 19(4):293-299. PubMed ID: 30892103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa-induced dyskinesia is preceded by increased levels of anxiety and motor impairment in Parkinson's disease patients.
    Dias CMV; Leal DAB; Brys I
    Int J Neurosci; 2023 Dec; 133(12):1319-1325. PubMed ID: 35603453
    [No Abstract]   [Full Text] [Related]  

  • 7. Amantadine Extended-Release (GOCOVRI
    Paik J; Keam SJ
    CNS Drugs; 2018 Aug; 32(8):797-806. PubMed ID: 30088203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa-induced dyskinesias.
    Fabbrini G; Brotchie JM; Grandas F; Nomoto M; Goetz CG
    Mov Disord; 2007 Jul; 22(10):1379-1389. PubMed ID: 17427940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.
    Tran TN; Vo TNN; Frei K; Truong DD
    J Neural Transm (Vienna); 2018 Aug; 125(8):1109-1117. PubMed ID: 29971495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Subthalamic Deep Brain Stimulation on Levodopa-Induced Dyskinesia in Parkinson's Disease.
    Kim JH; Chang WS; Jung HH; Chang JW
    Yonsei Med J; 2015 Sep; 56(5):1316-21. PubMed ID: 26256974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noradrenergic drugs for levodopa-induced dyskinesia.
    Colosimo C; Craus A
    Clin Neuropharmacol; 2003; 26(6):299-305. PubMed ID: 14646609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between the phenotype of Parkinson's disease and levodopa-induced dyskinesia.
    Zhang YH; Tang BS; Song CY; Xu Q; Lou MX; Liu ZH; Yu RH; Yan XX; Guo JF
    Neurosci Lett; 2013 Nov; 556():109-12. PubMed ID: 24135335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-dopa-induced dyskinesia and stereotactic surgery for Parkinson's disease.
    Guridi J; Obeso JA; Rodriguez-Oroz MC; Lozano AA; Manrique M
    Neurosurgery; 2008 Feb; 62(2):311-23; discussion 323-5. PubMed ID: 18382309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct effect of subthalamic nucleus stimulation on levodopa-induced peak-dose dyskinesia in patients with Parkinson's disease.
    Katayama Y; Oshima H; Kano T; Kobayashi K; Fukaya C; Yamamoto T
    Stereotact Funct Neurosurg; 2006; 84(4):176-9. PubMed ID: 16905880
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of levodopa-associated motor complications in patients with Parkinson's disease.
    Jankovic J; Stacy M
    CNS Drugs; 2007; 21(8):677-92. PubMed ID: 17630819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.
    Vijayakumar D; Jankovic J
    Drugs; 2016 May; 76(7):759-77. PubMed ID: 27091215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease.
    Utsumi H; Okuma Y; Kano O; Suzuki Y; Iijima M; Tomimitsu H; Hashida H; Kubo S; Suzuki M; Nanri K; Matsumura M; Murakami H; Hattori N;
    Intern Med; 2013; 52(3):325-32. PubMed ID: 23370739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).
    Oertel W; Eggert K; Pahwa R; Tanner CM; Hauser RA; Trenkwalder C; Ehret R; Azulay JP; Isaacson S; Felt L; Stempien MJ
    Mov Disord; 2017 Dec; 32(12):1701-1709. PubMed ID: 28833562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.